keyword
MENU ▼
Read by QxMD icon Read
search

Zaire

keyword
https://www.readbyqxmd.com/read/28985239/safety-and-immunogenicity-of-rvsv%C3%AE-g-zebov-gp-ebola-vaccine-in-adults-and-children-in-lambar%C3%A3-n%C3%A3-gabon-a-phase-i-randomised-trial
#1
Selidji T Agnandji, José F Fernandes, Emmanuel B Bache, Régis M Obiang Mba, Jessica S Brosnahan, Lumeka Kabwende, Paul Pitzinger, Pieter Staarink, Marguerite Massinga-Loembe, Verena Krähling, Nadine Biedenkopf, Sarah Katharina Fehling, Thomas Strecker, David J Clark, Henry M Staines, Jay W Hooper, Peter Silvera, Vasee Moorthy, Marie-Paule Kieny, Akim A Adegnika, Martin P Grobusch, Stephan Becker, Michael Ramharter, Benjamin Mordmüller, Bertrand Lell, Sanjeev Krishna, Peter G Kremsner
BACKGROUND: The rVSVΔG-ZEBOV-GP vaccine prevented Ebola virus disease when used at 2 × 107 plaque-forming units (PFU) in a trial in Guinea. This study provides further safety and immunogenicity data. METHODS AND FINDINGS: A randomised, open-label phase I trial in Lambaréné, Gabon, studied 5 single intramuscular vaccine doses of 3 × 103, 3 × 104, 3 × 105, 3 × 106, or 2 × 107 PFU in 115 adults and a dose of 2 × 107 PFU in 20 adolescents and 20 children. The primary objective was safety and tolerability 28 days post-injection...
October 2017: PLoS Medicine
https://www.readbyqxmd.com/read/28915404/dynamic-phosphorylation-of-ebola-virus-vp30-in-np-induced-inclusion-bodies
#2
Clemens Lier, Stephan Becker, Nadine Biedenkopf
Zaire Ebolavirus (EBOV) causes a severe feverish disease with high case fatality rates. Transcription of EBOV is dependent on the activity of the nucleocapsid protein VP30 which represents an essential viral transcription factor. Activity of VP30 is regulated via phosphorylation at six N-terminal serine residues. Recent data demonstrated that dynamic phosphorylation and dephosphorylation of serine residue 29 is essential for transcriptional support activity of VP30. To analyze the spatio/temporal dynamics of VP30 phosphorylation, we generated a peptide antibody recognizing specifically VP30 phosphorylated at serine 29...
September 12, 2017: Virology
https://www.readbyqxmd.com/read/28878074/cooperation-of-the-ebola-proteins-vp40-and-gp1-2-with-bst2-to-activate-nf-%C3%AE%C2%BA%C3%AE-independently-of-virus-like-particle-trapping
#3
Maryan G Rizk, Christopher F Basler, John Guatelli
BST2 is a host protein with dual functions in response to viral infections: it traps newly assembled enveloped virions at the plasma membrane of infected cells, and it induces NF-κβ activity, especially in the context of retroviral assembly. In this study, we examined whether Ebola virus proteins affect BST2-mediated induction of NF-κβ. We found that the Ebola matrix protein, VP40, and envelope glycoprotein, GP, each cooperate with BST2 to induce NF-κβ activity, with maximal activity when all three proteins are expressed...
September 6, 2017: Journal of Virology
https://www.readbyqxmd.com/read/28852031/infection-with-the-makona-variant-results-in-a-delayed-and-distinct-host-immune-response-compared-to-previous-ebola-virus-variants
#4
Krista Versteeg, Andrea R Menicucci, Courtney Woolsey, Chad E Mire, Joan B Geisbert, Robert W Cross, Krystle N Agans, Daniel Jeske, Ilhem Messaoudi, Thomas W Geisbert
Zaire Ebolavirus (ZEBOV) continues to pose a significant threat to human health as highlighted by the recent epidemic that originated in West Africa and the ongoing outbreak in the Democratic Republic of the Congo. Although the ZEBOV variant responsible for this epidemic (Makona) shares significant genetic similarity with previously identified variants (Kikwit and Mayinga), recent reports suggest slower disease progression in nonhuman primates. However, the pathogenesis caused by the new variant is not fully understood...
August 29, 2017: Scientific Reports
https://www.readbyqxmd.com/read/28822816/genetically-modified-rabies-virus-vectored-ebola-virus-disease-vaccines-are-safe-and-induce-efficacious-immune-responses-in-mice-and-dogs
#5
Lei Shuai, Xijun Wang, Zhiyuan Wen, Jinying Ge, Jinliang Wang, Dandan Zhao, Zhigao Bu
Ebola viruses (EBOVs) are zoonotic pathogens that cause EBOV disease (EVD) with high case fatality in humans. Currently, EVD vaccines are still under development in several countries. Here, we generated two recombinant rabies viruses (RABVs), rERAG333E/ZGP and rERAG333E/SGP, expressing the Zaire EBOV glycoprotein (ZGP) or Sudan EBOV glycoprotein (SGP) gene based on a modified ERA vaccine strain (rERAG333E) vector platform. The recombinant RABVs retained growth properties similar to those of the vector virus in BSR cell culture and efficiently expressed ZGP or SGP...
August 16, 2017: Antiviral Research
https://www.readbyqxmd.com/read/28795602/immunogenicity-of-the-recombinant-adenovirus-type-5-vector-based-ebola-vaccine-ad5-ebov-expressing-the-glycoprotein-of-the-2014-epidemic-strain-in-mice
#6
Ling Wang, Jing Jing Liu, Yan Kong, Li Hua Hou, Yu Hua Li
The 2014 Ebola outbreak in West Africa has brought great threat to the public health worldwide. Development of Ebola vaccine is urgent. A novel recombinant adenovirus type-5 vector-based Ebola vaccine (Ad5-EBOV) based on the 2014 Zaire Guinea epidemic strain was developed in China. A good safety profile and robust immune response elicited by Ad5-EBOV were confirmed in Phase I and Phase II clinical trial. However, clinical studies of Ebola vaccine are still at an early stage and no solid efficacy data for human beings yet...
August 10, 2017: Human Gene Therapy
https://www.readbyqxmd.com/read/28780120/vaccines-against-ebola-virus
#7
Navin Venkatraman, Daniel Silman, Pedro M Folegatti, Adrian V S Hill
We have just witnessed the largest and most devastating outbreak of Ebola virus disease, which highlighted the urgent need for development of an efficacious vaccine that could be used to curtail future outbreaks. Prior to 2014, there had been limited impetus worldwide to develop a vaccine since the virus was first discovered in 1976. Though too many lives were lost during this outbreak, it resulted in the significantly accelerated clinical development of a number of candidate vaccines through an extraordinary collaborative global effort coordinated by the World Health Organisation (WHO) and involving a number of companies, trial centres, funders, global stakeholders and agencies...
August 2, 2017: Vaccine
https://www.readbyqxmd.com/read/28756560/in-silico-analysis-of-the-cyanobacterial-lectin-scytovirin-new-insights-into-binding-properties
#8
Andrei Santos Siqueira, Alex Ranieri Jerônimo Lima, Rafael Conceição de Souza, Alberdan Silva Santos, João Lídio da Silva Gonçalves Vianez Júnior, Evonnildo Costa Gonçalves
Scytovirin is a lectin isolated from the cyanobacterium Scytonema varium that has shown activity against HIV, SARS coronavirus and Zaire Ebola virus. Its 95 amino acids are divided into two structural domains (SD), the first spanning amino acids 1-48 (SD1) and the second 49-95 (SD2). Interestingly, the domains are nearly identical but differ in their affinities for carbohydrates. With the aim of enhancing understanding of the binding properties of scytovirin, we performed molecular dynamics (MD) simulations of scytovirin complexed with Man4...
July 29, 2017: Molecular Biology Reports
https://www.readbyqxmd.com/read/28752209/plasma-lipidome-analysis-by-liquid-chromatography-high-resolution-mass-spectrometry-and-ion-mobility-of-hypertriglyceridemic-patients-on-extended-release-nicotinic-acid-a-pilot-study
#9
Véronique Ferchaud-Roucher, Mikaël Croyal, Thomas Moyon, Yassine Zair, Michel Krempf, Khadija Ouguerram
BACKGROUND: Plasma high triacylglycerols and low HDL-C concentration are associated with increased cardiovascular events. Extended-release nicotinic acid (ERN) was shown to reduce plasma triacylglycerols and total cholesterol but also to markedly increase high-density lipoprotein-cholesterol (HDL-C). No data on the effect of ERN on different species of triacylglycerol, cholesteryl ester, and phospholipids are available. In this study, we applied a nontargeted lipidomic approach to investigate the plasma and lipoproteins lipids profile of hypertriglyceridemic patients treated with ERN or a placebo in order to identify new lipids markers associated with this treatment...
July 28, 2017: Cardiovascular Drugs and Therapy
https://www.readbyqxmd.com/read/28713333/algevir-an-expression-system-for-microalgae-based-on-viral-vectors
#10
Bernardo Bañuelos-Hernández, Elizabeth Monreal-Escalante, Omar González-Ortega, Carlos Angulo, Sergio Rosales-Mendoza
The use of recombinant algae for the production of valuable compounds is opening promising biotechnological applications. However, the development of efficient expression approaches is still needed to expand the exploitation of microalgae in biotechnology. Herein, the concept of using viral expression vectors in microalgae was explored for the first time. An inducible geminiviral vector leading to Rep-mediated replication of the expression cassette allowed the production of antigenic proteins at high levels...
2017: Frontiers in Microbiology
https://www.readbyqxmd.com/read/28666874/anti-dengue-virus-activity-of-scytovirin-and-evaluation-of-point-mutation-effects-by-molecular-dynamics-and-binding-free-energy-calculations
#11
Andrei Santos Siqueira, Alex Ranieri Jerônimo Lima, Rafael Conceição de Souza, Alberdan Silva Santos, João Lídio da Silva Gonçalves Vianez Júnior, Evonnildo Costa Gonçalves
The absence of a specific treatment against DENV has led to intensive research into developing strategies for curing the infection. One lectin with high antiviral activity is scytovirin, which was isolated from the cyanobacterium Scytonema varium and has proven activity against HIV and Zaire Ebola Virus. To achieve the results presented here, we tested the affinity of full-length scytovirin, SD1 and SD2 separately, and six SD1 mutants for DENV glycoprotein E carbohydrate by Molecular Dynamics (MD) simulations and binding free energy calculations...
August 26, 2017: Biochemical and Biophysical Research Communications
https://www.readbyqxmd.com/read/28663587/challenge-of-liquid-stressed-protective-materials-and-environmental-persistence-of-ebola-virus
#12
Aidan M Nikiforuk, Todd A Cutts, Steven S Theriault, Bradley W M Cook
After the largest Ebola virus outbreak in history, experts have attempted to answer how the Zaire ebolavirus species emerged in West Africa and caused chains of human-to-human transmission. The widespread and untimely infection of Health Care Workers (HCW) in the affected countries accelerated spread of the virus within the community. Among the reasons attributed to this trend, it must be considered that HCW were exposed to the virus in their occupational environment. The contribution of environmental conditions to the spread of Ebola in West Africa was examined by investigating the effect of temperature/humidity on the virus's environmental persistence and by modeling if saturation (liquid stress) allows for penetration of Ebola virus through personal protective equipment (PPE)...
June 29, 2017: Scientific Reports
https://www.readbyqxmd.com/read/28647166/clinical-development-of-a-recombinant-ebola-vaccine-in-the-midst-of-an-unprecedented-epidemic
#13
Beth-Ann G Coller, Jeffrey Blue, Rituparna Das, Sheri Dubey, Lynn Finelli, Swati Gupta, Frans Helmond, Rebecca J Grant-Klein, Kenneth Liu, Jakub Simon, Sean Troth, Susan VanRheenen, Julie Waterbury, Ashley Wivel, Jayanthi Wolf, D Gray Heppner, Tracy Kemp, Rick Nichols, Thomas P Monath
The 2014-2016 Ebola outbreak caused over 28,000 cases and 11,000 deaths. Merck & Co. Inc., Kenilworth, NJ USA and NewLink Genetics are working with private and public partners to develop and license an Ebola vaccine that was evaluated extensively during the outbreak. The vaccine referred to as V920 is a recombinant vesicular stomatitis virus (rVSV) in which the VSV-G envelope glycoprotein (GP) is completely replaced by the Zaire ebolavirus GP (rVSVΔG-ZEBOV-GP). Eight Phase I and four Phase II/III clinical trials enrolling approximately 17,000 subjects were conducted in parallel to the outbreak to assess the safety, immunogenicity, and/or efficacy of V920...
June 21, 2017: Vaccine
https://www.readbyqxmd.com/read/28630358/assessing-the-safety-and-immunogenicity-of-recombinant-vesicular-stomatitis-virus-ebola-vaccine-in-healthy-adults-a-randomized-clinical-trial
#14
RANDOMIZED CONTROLLED TRIAL
May S ElSherif, Catherine Brown, Donna MacKinnon-Cameron, Li Li, Trina Racine, Judie Alimonti, Thomas L Rudge, Carol Sabourin, Peter Silvera, Jay W Hooper, Steven A Kwilas, Nicole Kilgore, Christopher Badorrek, W Jay Ramsey, D Gray Heppner, Tracy Kemp, Thomas P Monath, Teresa Nowak, Shelly A McNeil, Joanne M Langley, Scott A Halperin
BACKGROUND: The 2013-2016 Ebola virus outbreak in West Africa was the most widespread in history. In response, alive attenuated recombinant vesicular stomatitis virus (rVSV) vaccine expressing Zaire Ebolavirus glycoprotein (rVSVΔG-ZEBOV-GP) was evaluated in humans. METHODS: In a phase 1, randomized, dose-ranging, observer-blind, placebo-controlled trial, healthy adults aged 18-65 years were randomized into 4 groups of 10 to receive one of 3 vaccine doses or placebo...
June 19, 2017: CMAJ: Canadian Medical Association Journal, Journal de L'Association Medicale Canadienne
https://www.readbyqxmd.com/read/28628441/novel-retinal-lesion-in-ebola-survivors-sierra-leone-2016
#15
Paul J Steptoe, Janet T Scott, Julia M Baxter, Craig K Parkes, Rahul Dwivedi, Gabriela Czanner, Matthew J Vandy, Fayiah Momorie, Alimamy D Fornah, Patrick Komba, Jade Richards, Foday Sahr, Nicholas A V Beare, Malcolm G Semple
We conducted a case-control study in Freetown, Sierra Leone, to investigate ocular signs in Ebola virus disease (EVD) survivors. A total of 82 EVD survivors with ocular symptoms and 105 controls from asymptomatic civilian and military personnel and symptomatic eye clinic attendees underwent ophthalmic examination, including widefield retinal imaging. Snellen visual acuity was <6/7.5 in 75.6% (97.5% CI 63%-85.7%) of EVD survivors and 75.5% (97.5% CI 59.1%-87.9%) of controls. Unilateral white cataracts were present in 7...
July 2017: Emerging Infectious Diseases
https://www.readbyqxmd.com/read/28606591/safety-and-immunogenicity-of-the-rvsv%C3%A2-g-zebov-gp-ebola-virus-vaccine-candidate-in-healthy-adults-a-phase-1b-randomised-multicentre-double-blind-placebo-controlled-dose-response-study
#16
RANDOMIZED CONTROLLED TRIAL
D Gray Heppner, Tracy L Kemp, Brian K Martin, William J Ramsey, Richard Nichols, Emily J Dasen, Charles J Link, Rituparna Das, Zhi Jin Xu, Eric A Sheldon, Teresa A Nowak, Thomas P Monath
BACKGROUND: The 2014 Zaire Ebola virus outbreak highlighted the need for a safe, effective vaccine with a rapid onset of protection. We report the safety and immunogenicity of the recombinant vesicular stomatitis virus-Zaire Ebola virus envelope glycoprotein vaccine (rVSV∆G-ZEBOV-GP) across a 6 log10 dose range in two sequential cohorts. METHODS: In this phase 1b double-blind, placebo-controlled, dose-response study we enrolled and randomly assigned healthy adults (aged 18-61 years) at eight study sites in the USA to receive a single injection of vaccine or placebo, administered by intramuscular injection...
August 2017: Lancet Infectious Diseases
https://www.readbyqxmd.com/read/28592526/novel-cross-reactive-monoclonal-antibodies-against-ebolavirus-glycoproteins-show-protection-in-a-murine-challenge-model
#17
James Duehr, Teddy John Wohlbold, Lisa Oestereich, Veronika Chromikova, Fatima Amanat, Madhusudan Rajendran, Sergio Gomez-Medina, Ignacio Mena, Benjamin R tenOever, Adolfo García-Sastre, Christopher F Basler, Cesar Munoz-Fontela, Florian Krammer
Out of an estimated 31,100 cases since their discovery in 1976, ebolaviruses have caused approximately 13,000 deaths. The vast majority (∼11,000) of these occurred during the 2013-2016 West African epidemic. Three out of five species in the genus are known to cause Ebola Virus Disease in humans. Several monoclonal antibodies against the ebolavirus glycoprotein are currently in development as therapeutics. However, there is still a paucity of monoclonal antibodies that can cross-react between the glycoproteins of different ebolavirus species, and the mechanism of these monoclonal antibody therapeutics is still not understood in detail...
August 15, 2017: Journal of Virology
https://www.readbyqxmd.com/read/28574091/macrocyclic-peptide-inhibitors-for-the-protein-protein-interaction-of-zaire-ebola-virus-protein-24-and-karyopherin-alpha-5
#18
Xiao Song, Lu-Yi Lu, Toby Passioura, Hiroaki Suga
Ebola virus infection leads to severe hemorrhagic fever in human and non-human primates with an average case fatality rate of 50%. To date, numerous potential therapies are in development, but FDA-approved drugs or vaccines are yet unavailable. Ebola viral protein 24 (VP24) is a multifunctional protein that plays critical roles in the pathogenesis of Ebola virus infection, e.g. innate immune suppression by blocking the interaction between KPNA and PY-STAT1. Here we report macrocyclic peptide inhibitors of the VP24-KPNA5 protein-protein interaction (PPI) by means of the RaPID (Random non-standard Peptides Integrated Discovery) system...
June 21, 2017: Organic & Biomolecular Chemistry
https://www.readbyqxmd.com/read/28573609/ebolavirus-an-overview-of-molecular-and-clinical-pathogenesis
#19
Veronica Vine, Dana P Scott, Heinz Feldmann
Ebolaviruses cause severe, often fatal hemorrhagic fever in Central, East, and West Africa. Until recently, they have been viewed as rare but highly pathogenic infections with regional, but limited, global public health impact. This view has changed with the emergence of the first epidemic of Ebola hemorrhagic fever in West Africa. In this chapter we provide an introduction of the pathogenesis of ebolaviruses as well as a description of clinical disease features. We also describe the current animal models used in ebolavirus research, detailing each model's unique strengths and weaknesses...
2017: Methods in Molecular Biology
https://www.readbyqxmd.com/read/28549145/six-month-safety-data-of-recombinant-vesicular-stomatitis-virus-zaire-ebola-virus-envelope-glycoprotein-vaccine-in-a-phase-3-double-blind-placebo-controlled-randomized-study-in-healthy-adults
#20
Scott A Halperin, Jose R Arribas, Richard Rupp, Charles P Andrews, Laurence Chu, Rituparna Das, Jakub K Simon, Matthew T Onorato, Kenneth Liu, Jason Martin, Frans A Helmond
Background: This study (NCT02503202) evaluated the safety of recombinant vesicular stomatitis virus-Zaire Ebola virus envelope glycoprotein vaccine (rVSVΔG-ZEBOV-GP). Methods: Overall, 1197 subjects were randomized 2:2:2:2:1; 1194 were vaccinated with 1 dose of 1 of 3 lots of rVSVΔG- ZEBOV-GP (2 × 107 plaque-forming units [pfu], n = 797; combined-lots group), a single high-dose lot of rVSVΔG-ZEBOV-GP (1 × 108 pfu, n = 264; high-dose group), or placebo (n = 133)...
June 15, 2017: Journal of Infectious Diseases
keyword
keyword
15409
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"